Metabolism Imaging-genomics for Predicting the Surgical Outcomes of Colorectal Cancer

NCT06614660 · tracked via the Priya Life Science China tracker

Sponsor

First Affiliated Hospital of Chongqing Medical University

Phase

Observational

Started

2024-09-01

Last updated

2024-09-27

Condition(s) studied

Colorectal CancerImagingMetabolomicsPrognosisGenomics

Investigational drug(s) / intervention(s)

Metabolism genomics and imaging genomics

Metabolism genomics and imaging genomics: Pre-operative imaging images of the patient were collected prior to surgery, and 2 ml of the patient\'s blood specimen was collected to collect metabolism genomics and imaging genomics.

Study summary

In this study, the investigators constructed an imaging-metabolism prediction model for colorectal cancer by analysing the imaging and metabolomics features of colorectal cancer, in order to further adjust and guide the treatment plan.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion criteria: * met the diagnostic criteria for gastrointestinal tumours; * age \&gt;18 years; * planned to undergo surgery for gastrointestinal tumours according to the guidelines; * signed an informed consent form; and e) agreed to undergo a biopsy in order to collect tissue from the tumour lesion. Exclusion criteria: * contraindications to imaging; * withdrawal from the study cohort midway; * metastatic foci in the liver, lung or other distant organs confirmed by CT, MRI or ultrasound imaging; * gastrointestinal tumours combined with haemorrhage, obstruction or perforation; * women who were pregnant, breastfeeding or planning to become pregnant during the study period.

Primary outcome measure(s)

Overall survival — From date of diagnosis until the date of death from any cause or or loss to follow-up, whichever came first, assessed up to 60 months.
Overall survival was defined as time from date of diagnosis until the date of death from any cause or or loss to follow-up.

Trial sites (1)

Facility	City	Region	Status
The First Affiliated Hospital of Chongqing Medical University	Chongqing	Chongqing Municipality

More First Affiliated Hospital of Chongqing Medical University trials in China

Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment Recruiting

Sertraline Combined With Multi-Strain Probiotics for Adolescent Depression Recruiting

Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study Starting soon

Metabolomics Predictors for Metabolic Disease Remission After Metabolic Syndrome Surgery. Active, not recruiting

An Integrated Multi-omics Study on the Molecular Mechanisms of Ureteral Stricture Starting soon

Other trials for the same condition

Sentinel Lymph Node Sampling for Patients With Middle-high Risk Endometrial Cancer Confined to the Uterus Active, not recruiting

Construction and Empirical Research of the Applicable Baduanjin Protocol for Patients With Colorectal Cancer Enterostomy Starting soon

Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors Recruiting

Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy. Starting soon

A Clinical Study of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in the Treatment of Advanced Colorectal Cancer Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06614660 on ClinicalTrials.gov ↗ ← All trials in China